Rep. Thomas H. Kean Jr. of New Jersey has filed a Periodic Transaction Report under the STOCK Act disclosing a sale of Stryker Corporation common stock (NYSE: SYK). The transaction, dated July 22, 2026, was made personally by the congressman and is valued in the disclosed range of $1,001 to $15,000. The holding was reported through State Street Bank & Trust Co., a common custodial arrangement for congressional brokerage accounts.
STOCK Act filings do not require members of Congress to disclose an exact sale price, only a value range, so the precise proceeds from this transaction remain undisclosed. Our internal tracking system has classified this filing as a ‘congress sale’ signal, meaning it will be logged alongside other recent disclosed sales of the same security for pattern comparison purposes.
A Notable Overlap With Insider Activity
What makes this filing worth watching is its timing relative to activity from within Stryker itself. Company insider Kimberly Ann Montagnino also sold shares of SYK on August 1, 2026, in a transaction valued at $50,484, according to separate disclosure records. That sale occurred within roughly ten days of Rep. Kean’s reported transaction date, placing both filings inside the same 30-day window.
To be clear, there is no indication in either filing of coordination, shared information, or any wrongdoing. STOCK Act reporting exists precisely so that the public can independently observe transactions like these; the requirement to disclose is a matter of law, not evidence of any impropriety. Members of Congress and corporate insiders operate under separate disclosure regimes, and overlapping sale dates for a widely held stock like Stryker can and do occur without any connection between the parties involved.
Still, when a member of Congress and a company insider disclose sales of the same security in close proximity, it becomes a data point worth logging for readers who track these patterns over time. Stryker is a large, actively traded medical technology company, and its shares move through many institutional and individual portfolios independent of any single filer’s activity.
Readers who follow broader portfolio-level disclosures, rather than single transactions, may also be interested in our ongoing coverage of Veritas Asset Management LLP’s quarterly 13F portfolio moves, which tracks how institutional investors adjust their holdings over time using a different disclosure framework than the STOCK Act.
As with all congressional trading disclosures, this filing will remain part of the public record, and any subsequent transactions involving Rep. Kean or Stryker Corporation will be reflected in future filings as they become available.